Ono Pharmaceutical Co., Ltd (Head Office: Osaka City, President and Representative Director: Gyo Sagara; 'ONO') announced today its resolution to establish a specified subsidiary, Ono Venture Investment Fund I, L.P. (the Fund), and a wholly-owned subsidiary, Ono Venture Investment, Inc. ('OVI') to manage the investment fund.

Aim of the establishments

For future access to innovative technologies/novel therapeutic drug targets and collaboration with early stage startup companies, OVI makes a strategic investment in such startup companies with cutting-edge technologies.

Future Guidance.

We believe an impact of this incident on our company's financial results for the current fiscal year would be marginal, but any matter that may have a significant impact will be promptly disclosed in the future.

Contact:

Email: publicrelations@ono.co.jp

(C) 2020 Electronic News Publishing, source ENP Newswire